Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in ...

GSK is pumping £50 million (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge ...

The Cambridge-GSK Translational Immunology Collaboration builds on an existing scientific relationship between the biopharma company and the university, with the aim of improving outcomes for patients ...

Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. | ...

GSK has announced a £50m ($54.3m) investment in a new partnership with the University of Cambridge and Cambridge University ...

An 800% increase in licensing deal values indicates growing confidence in mRNA technology, but some vaccine producers are ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

GSK's gepotidacin, an oral antibiotic for uUTIs, could be the first in over 20 years. The FDA granted Priority Review with a ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...